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Segmental characterization of defects in collecting tuhule acidification.
The aim of this study was to investigate cortical collecting tubule (CCT)
function in normal individuals and in patients with distal renal tubular
acidosis (DRTA) using furosemide (80 mg orally) as a tool to stimulate
H+ and K+ secretion by enhancing Na delivery and transport in this
nephron segment. In ten normal subjects, furosemide resulted in a fall
in urine pH below 5.5 and an increase in net acid and K+ excretion.
These effects were obliterated by amiloride, a drug which decreases
transtubular epithelial voltage (lumen—negative) in the CCT by blocking
Na reabsorption. In 13 patients with DRTA, defined by failure to lower
urine pH below 5.5 during acidemia, three distinctive responses to
furosemide were found. In six patients with the hypcrkalemic variety,
furosemidc failed to lower urine pit below 5.5 and resulted in a blunted
increase in K+ excretion, thereby suggesting that a normal transssibular
voltage in the CCT could not be geoerated in such patients. In five
patients with classic RTA, furosemide failed to lower urine p1-I below
5.5, but K+ excretion increased normally. The increase in K+ excre-
tion indicated that a normal transtuhular voltage in the CCT could be
generated, while the inability to lower urine pH denotes the presence of
a proton pump defect involving the CCT. In two patients with classic
RTA, furosemide resulted in both a normal fall in urine pH and an
increase in K+ excretion, thereby indicating that the CCT was normal
in regards to both proton pump function and in its ability to generate a
normal transtubular voltage. By exclusion, their defect in distal acidi-
fication was ascribed to a proton pump defect confincd to the medullary
portion of the collecting tubule. These patterns were also found after
the administration of sodium sulfate. It is proposed that evaluation of
the ability to lower urine pH and increase K+ excretion after furose-
mide or sodium sulfate may allow for the characterization of the type of
defect underlying the DRTA syndromes and its localization within the
collecting tubule.
The characterization of tubtilar defects in urinary acidifica-
tion was first directed to separate those involving the distal
nephron (type I RTA) from those affecting the proximal neph-
ron (type TI RTA) [1—51. More recent studies in humans have
provided evidence for the notion that the distal renal tubular
acidosis (DRTA) syndrome may develop from various distinc-
tive derangements in the process of distal hydrogen ion secre-
tion [6—101. These studies, however, did not focus on the
precise site in the distal nephron involved in the pathogenesis of
the syndrome. Much of the knowledge applied to the charac-
terization and classification of experimental [11—151 and clinical
defects [3, 6—101 in distal hydrogen ion secretion came from
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studies in the urinary turtle bladder [13, 16—18]. This membrane
has transport characteristics which in the mammalian collecting
tubule appear to be well demarcated to the cortical and medul-
lary segments [181. Accordingly, extrapolation of data from
turtle bladder studies to the whole animal setting does not
permit the localization of a defect in acidification to the cortical
or medullary portions of the collecting tubule.
The lumen—negative potential difference usually prevailing in
the cortical collecting tubule (Cci') which is generated by
active Na reabsorption favors the secretion of H+ ions and K+
[19—23]. Maneuvers that obliterate lumen electro-negativity in
the CCT have been shown to inhibit H+ and K+ secretion [19,
21, 231. Tn contrast, the medullary collecting tubule (MCT)
secretes H± independently of Na transport [23—251. From these
in vitro observations, it seems logical to postulate that assess-
ment of acidification by the CCT in vivo should be possible
using a manuever that enhances only sodium—dependent (that
is, voltage—dependent H+ secretion). Furosemide should pro-
vide an optimal tool to assess sodium—dependent acidification
by the CCT for the following reasons. First, by blocking NaCI
reabsorption in the thick ascending loop of Henle, it increases
Na delivery to the collecting tubule. Second, by increasing Na
reabsorption in the CCT it should result in the creation of a
favorable transtubular voltage (lumen—negative), and thus en-
hancement of H+ and K+ secretion. This postulation requires
that a stimulatory effect of furosemide on CCT acidification and
K+ excretion be totally or partially prevented by amiloride, an
agent which blocks Na reabsorption and thereby inhibits acid-
ification [19] and K+ secretion [22] in the CCT1. Third, furo-
semide does not exert any direct effect on acidification by the
collecting tubule [291 or other epithelial capable of H+ secre-
tion, while other diuretics could stimulate H+ secretion by a
direct effect [30], Finally, furosemide (and other loop diuretics)
have been shown to stimulate urinary acidification, thereby
setting a precedent for a potential use to evaluate distal acidi-
fication [31—36].
This study was undertaken to test the hypothesis that in
'Micropuncture studies have shown that the distal tubule is an
important site of K+ secretion and that amiloride inhibits this process
[26]. More recent work has shown that the superficial late distal tubule,
which is the site of K 1- secretion within the distal tubule, is ultrastruc-
turally similar to the CCT [27, 28]. Hence, the late distal tubule is also
referred as the initial collecting tubule [27, 28]. lu the present study this
segment is included under the term CCT.
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Table 1. General feature s of patients with distal renal tubular acidosisa
Blood Blood
Plasma Plasma Plasma Plasma HCO1 pCO2 PRA*
creatinine GFR K mEq/ Na mEq/ Cl mEq/ mEq/ mEq/ Blood Urine ng/ml/ PA* PA/K
Patient age/sex diagnosis mg/dl mi/rn liter liter liter liter liter pH pH hr ng/dl ratio*
Classic RTA
1 36/F Idiopathic DRTA 1.5 48 4.2 140 106 18 30 7.40 7.45 7.4 36 9.6
2 l6/M Idiopathic DRTA 0.7 124 3.6 138 105 17 30 7.37 7.21 7.6 Il 3.2
3 55/F Idiopathic DRTA 1.7 48 4.5 136 110 19 39 7.32 5.81 1.5 28 5.2
4 63/F Idiopathic DRTA 1.4 57 4.6 139 106 22 32 7.43 6.93 2.3 54 12
5 20/F Idiopathic DRTA and 0.8 84 3.0 139 110 17.5 35 7.32 6.92 — 19 4.8
congenital deafness
6 26/F Chronic active 1.0 62 4.7 145 113 17 35 7.30 5.76 6.0 35 12
hepatitis
7 60/F Nephrolithiasis 6.0 7.6 4.6 132 111 12 35 7.14 6.30 77 50 11
Mean 1.9 62 4.2 138 109 17.5 34 7.33 6.63 17 33 8.3
±SE ±0.7 ±13 ±0.2 ±1.5 ±1.1 ±1.1 ±1.2 ±0.04 ±0.25 ±12 ±5.9 ±1.4
Hyperkalemic DRTA
1 34/M Sickle cell 5.4 27 6.0 138 103 7.2 16 7.27 5.58 0.8 19 3.7
nephropathy
2 33/F Sickle cell 1.5 48 6.2 140 110 17 32 7.35 5.72 2.9 25 5.7
nephropathy
3 56/F Chronic 2.5 32 5.6 142 109 17 34 7.31 5.86 0.7 6.0 1.4
pyelonephritis,
diabetes
4 70/M Obstructive 4.0 12 6.2 124 92 15 25 7.40 6.34 3.1 6.6 1.3
uropathy
5 72/M Obstructive 2.1 66 6.6 132 107 16 31 7.32 6.92 0.8 3.9 0.8
uropathy
6 54/MChronicglomerulo- 5.9 8.5 5.7 140 111 7.9 17 7.29 6.77 0.1 9.4 2.2
nephritis, obstructive
uropathy
Mean 3.6 32 6.0 136 105 13 26 7.32 6.19 1.4 12 2.5
±SE ±0.7 ±9.0 ±0.2 ±2.8 ±2.9 ±1.8 ±3.2 ±0.02 ±0.22 ±0.05 ±3.4 ±0.7
Abbreviations are: PRA, denotes plasma renin activity; PA, plasma aldosterone; , values obtained after furosemide administration; PA/K,
plasma aldosterone divided by plasma potassium after furosemide administration.
normal subjects sodium—dependent H+ and K+ secretion by
the CCT can be stimulated using furosemide, and that such
effect is obliterated by amiloride. Furosemide was also em-
ployed in patients with DRTA, reasoning that analysis of the
acidification and kaliuretic response to this diuretic, together
with the evaluation of plasma K+, would permit the character-
ization of the type of distal acidification defect and its localiza-
tion within the collecting tubule.
Methods
Thirteen patients with DRTA and ten normal subjects were
studied. Seven patients had the features of the classic RTA
form (type I RTA) which was idiopathic (patients 1 to 4),
associated with congenital deafness (patient 5), chronic active
hepatitis (patient 6), and recurrent nephrolithiasis (patient 7)
(Table 1). Two patients with idiopathic RTA were from the
same family, mother and son, respectively. Only the mother
(patient I) developed nephrolithiasis. The remaining two (pa-
tients 3 and 4) had long standing nephrocalcinosis. Plasma K+
at the time of the study was normal in all seven patients. Mild
hypokalemia, however, had been documented in four (patients
1, 3, 4 and 5) in previous evaluations. Plasma aldosterone (PA)
was normal or elevated (Table 1). Plasma creatinine was slightly
elevated in three (patients 1, 3 and 4), normal in three (patients
2, 5 and 6), and markedly elevated in one (patient 7). The
diagnosis of DRTA was made after measuring urine pH and acid
excretion while patients had metabolic acidosis. Urine pH was
persistently higher than 5.5 in all of them. In some patients (3,
4, and 6) ammonium chloride was given at a dose of 0.1 g per
kilo body weight for three days to further verify their inability to
lower urine pH below 5.5. Fractional HCO3 excretion when
plasma HCO3 was higher than 22 mEq/liter was less than 5% in
all patients, thereby excluding any significant bicarbonate wast-
age in the proximal nephron 15].
Six patients had the hyperkalemic form of DRTA. The
underlying causes of their renal disease are listed in Table 1.
Plasma creatinine was elevated and plasma K+ higher than 5.5
mEq/liter in all of them. Since urine pH could not be lowered
below 5.5 during acidemia, all six patients were felt to have
hyperkalemic DRTA [7, 81. PA measured after plasma K+ had
been normalized by dietary K restriction and the use of
Kayaxelate was in the normal range in two patients (I and 2)
and low in the remaining four (patients 3 to 6) (Table 1). The
PAIPK ratio was greater than 3.5 in two (patients 1 and 2) and
lower than 2.5 in the remaining four. Patients 3 through 6 were
classified as having both hyperkalemic DRTA and aldosterone
deficiency [7, 8, 15]. The following protocols were followed.
1. Furosemide administration. After completing baseline
urine collections for determination of GFR (measured by the
clearance of creatinine), plasma and urine electrolytes, urine
pH, and acid excretion, furosemide was given orally at a dose of
80 mg. This relatively large dose was chosen because many of
our patients had some degree of renal insufficiency. Urine
samples were obtained at hourly intervals or whenever the
subjects requested to urinate, which at times was as frequently
as every 15 minutes. The data for all the collections were
averaged for hourly periods for four hours, Venous blood
samples for plasma electrolytes, plasma renin activity (PRA),
and PA were obtained before and approximately three hours
after the administration of furosemide. Urinary losses of water
and electrolytes were not replaced. Blood was drawn while
patients were in the sitting position. All 13 patients with DRTA,
10 normal subjects, and four control subjects with chronic renal
insufficiency underwent this protocol.
2. Amiloride plus furosemide administration. This protocol
was identical to that described for furosemide except that
amiloride at an oral dose of 20 mg was given together with
furosemide. Four of the ten normal subjects studied in response
to furosemide underwent this study. All subjects gave written
consent according to a protocol approved by the Institutional
Board Review of the University of Illinois College of Medicine
at Chicago.
3. Sodium sulfate infusion. This protocol, unlike the previous
ones, included the administration of fludrocortisone (1 mg
orally) the night before the infusion 6—8I. The next morning,
two timed urine collections were obtained, and 500 ml of a 4%
solution of sodium sulfate was then infused over 45 to 60
minutes. Urine specimens were obtained approximately 60,
120, 180, and 240 minutes after the beginning of the infusion. All
patients with classic RTA except one (patient 5) underwent this
protocol.
Plasma and urine electrolytes, blood pH and carbon dioxide
tension, titratable acidity, and ammonium were determined as
previously described 17]. PA and PRA were measured by
radioimmunoassay (Diagnostic Products, Los Angeles, Califor-
nia and E.R. Squibb and Sons, Princeton, New Jersey, USA,
respectively). Statistical analysis was performed with the t-test
for paired or unpaired data when appropriate. Values are
reported as means SEM.
Results
Effect of furosemide in normal subjects
Urine pH prior to furosemide administration was 5.72 0.2
(range 5.16 to 7.29). After furosemide it fell below 5.3 in all
subjects regardless of the prevailing urine pH observed prior to
its administration. The lowest urine pH was 4.85 0.05 (range
4.60 to 5.07) and was associated with a significant increase in
titratable acidity (from 24 4.5 to 37 4.2 rEq/min, P <
0.025), ammonium (from 13 2.2 to 19 3.7 Eq/min, P <
0.025), and net acid (from 33 8.3 to 56 6.9 Eq/min, P <
0.02) (Fig. 1). HCO3 excretion fell (from 3.8 3.2 to 0.1 0.4
xEq/min) but not significantly (P > 0.05).
Furosemide resulted in an increase in urine flow which was
maximal (14 1 .8 mI/mm) during the second hour following its
administration. The excretion of Na, Cl, K, and HCO3 was also
maximal in the second hour and declined during the third and
fourth hours. By linear regression analysis, a direct correlation
between urine pH (y) and urine flow (x) was found after
furosemide: y = 4.7 + 0.08 x, r 0.81, (P <0.001). Thus, when
urine flow was maximal, urine p1-I was the highest (Fig. 2). Most
points with a urine flow above 10 mI/mm were obtained during
the second hour, a time when urine pH (5.97 0.2) was not
significantly different from that observed prior to furosemide
(5.72 0.2). The fall in urine pH occurred in most subjects
during the third and fourth hours (5.09 0.1 and 4,95 0.1 pH
units, respectively).
After furosemide GFR fell significantly (from 153 14 to 122
10 ml/min (P <0.005). Plasma K+ and plasma Cl fell slightly
(from 4.2 0.1 to 3.9 0.1 mEq/liter and from 102 1.6 to 96
1.3 mEq/liter, respectively, P < 0.005. Blood pH, plasma
I-1C03 and plasma Na did not change significantly. PRA in-
creased from 2.8 0.8 to 6.9 1.7 ng/ml/hr. but this difference
did not achieve statistical significance. PA did not increase
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Fig. 1. The effect ojJirose,nide (F) on urine p11,
titratable acid (TA), a,n,noniurn (NH4), and net
acid excretion in ten normal subjects. The data
shown in this figure were obtained when urine
pH after furosemide was the lowest. C denotes
data obtained immediately before furosemide
administration.
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Fig. 2. The relation between urine pH and urine flow after furosenzide
administration in JO normal subjects. (y 4.7 + 1.08 x, r = 0.81, P <
0.001).
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Fig. 3. The effect offurosemide (•) and furosemide + amiloride (0) on
urinary acidification in four normal subjects. The asterisk denotes a
significant difference between the two experimental conditions.
(from 22 5.9 to 24 8.2 ngldl). K excretion increased directly
as a function of both urine flow and Na excretion (see below).
Effect of furosemide and amiloride in normal subjects
The fall in urine pH and the increase in net acid excretion
elicited by furosemide alone was totally prevented when
amiloride was given (Fig. 3). In the third hour following the
administration of the two diuretics, urine flow was slightly but
significantly higher than when furosemide was given alone (8.9
0.7 and 7.4 1.0 mI/mm, respectively, P < 0.05). That the
lack of a fall in urine pH after furosemide and amiloride
administration was not due to the high urine flow is shown by
the lack of correlation between urine pH (y) and urine flow (x)
prevailing under these conditions: y 6.4 + 0.008 x, r = 0.14.
In contrast, a direct correlation between urine pH (y) and urine
flow (x) was found in the same four individuals when furose-
mide was given alone: y = 4.7 + 0.08 x, r = 0.87.
Neither ammonium nor titratable acid excretion increased
when furosemide was given with amiloride. HCO3 excretion
was higher after furosemide plus amiloride than after furose-
mide alone. Consequently, when both diuretics were used, net
acid excretion was reduced as a result of both increased HCO3
excretion and decreased acid excretion (Fig. 3). K+ excretion
increased only during the second hour following the adminis-
tration of furosemide and amiloride (from 74 10 to 143 21
tEq,/min, P <0.02), a time when urine flow was maximal. K+
excretion, at this time, was markedly lower than that observed
after the administration of furosemide alone (143 21 and 208
25 tEq/min, respectively, P < 0.02). By linear regression
analysis, K+ excretion (y) correlated directly with urine flow
(x) after furosemide: y = 89 + 7.8 x, r = 0.70, (P < 0.01), and
after amiloride and furosemide: y = 34 + 5.4 x, r = 0.62, (P <
0.01). K+ excretion after furosemide plus amiloride, however,
was lower than when furosemide was given alone, as shown by
the intercept (P < 0.001) of the regression lines depicting the
relationship between K+ excretion and urine flow (Fig. 4). A
direct correlation between K + excretion (y) and Na excretion
(x) was also found after furosemide: y = 92 + 0.06x, r = 0,70 (P
<0.01) and after furosemide and amiloride: y = 29 + 0.04 x r
= 0.61 (P < 0.01). At comparable rates of Na excretion,
however, K+ excretion after furosemide and amiloride was
lower than when furosemide was given alone, as shown by the
intercept (P < 0.001) of the lines depicting the relationship
between K+ and Na excretion (Fig. 5).
Effect of furosemide and sodum sulfate in patients with
classic RTA
As in normal subjects, the lowest urine pH was achieved in
the third or fourth hour after furosemide administration, a time
when the diuretic resulted in a modest but significant fall in
urine pH and an increase in net acid excretion (Table 2). The
increase in net acid excretion was largely the result of an
increase in titratable acid excretion because neither ammonium
nor HCO3 excretion changed significantly. PA did not change
(from 32 8.3 to 36 6.1 ng!dl) while PRA increased (from 8.4
4.8 to 19.8 14 xg/m1Ihr) but not significantly (P > 0.05).
In the seven patients with classic RTA considered together,
urine pH was higher and net acid excretion lower than those of
the 10 normal subjects (6.08 0.28 vs. 4.85 0.05, P < 0.001,
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Fig. 4. The relation between K+ excretion (UKV) and urine flow in 10
normal subjects given furosemide (•) and in four of them in whom
furosemide and amiloride were given together (0).
Furosemide
and 18 12 vs. 56 6.9 sEq/min, P < 0.02 respectively).
These differences were observed at comparable rates of urine
flow (5.8 1.4 vs. 4.8 0.7 mI/mm), Na excretion (550 139
vs. 541 85 pEq/min) and K excretion (110 21 vs. 133 22
tEq/min, respectively). PA was not significantly different be-
tween the two groups (36 6.1 and 24 8.2 ng/dl, respec-
tively).
Sodium sulfate infusion also resulted in a slight but significant
fall in urine pH and an increase in net acid excretion (Table 2).
The lowest urine pH obtained after sodium sulfate was almost
identical to that observed after furosemide (6.07 0.39 and 6.08
0.28, respectively). After sodium sulfate infusion, urine flow,
Na and K excretion were comparable to those prevailing during
the maximal stimulatory effect of furosemide on urinary acidi-
fication (Table 3). As anticipated, Cl excretion after sodium
sulfate was markedly lower than that observed after furosemide
(85 37 and 629 152 jsEq/min, respectively, P < 0.01).
The individual urine pH responses to furosemide and sodium
sulfate are shown in Fig. 6, left panel. In five patients (1, 2, 4,
5 and 7) urine pH after furoscmide remained higher than 6.0
while in the remaining two (patients 3 and 6) it fell below 5.3.
The patients in whom urine pH was higher than 6.0 after
furosemide also could not lower it below this level after sodium
sulfate infusion while in the remaining two it fell below 5.3 after
the administration of either agent. Net acid excretion after both
furosemide and sodium sulfate administration increased to a
greater extent in the later patients than in the former (Fig. 6,
right panel). K+ excretion increased after furosemide and after
sodium sulfate in all patients regardless of whether they were
able to lower urine pH or not (Fig. 7). Na excretion also
increased in all patients.
Discussion
This study shows that in normal individuals, furosemide
stimulates voltage—dependent H+ and K+ secretion in the
CCT, and suggests that this agent can be utilized to disclose the
segmental localization of the tubular defect underlying the
DRTA syndromes. The notion that the increase in distal Na
reabsorption secondary to furosemide administration results in
enhancement of voltage—dependent acidification in the CCT
was validated by showing that the fall in urine pH and the
increase in net acid excretion elicited by furosemide was
obliterated by amiloride (Fig. 3). The data also indicates that the
stimulatory effect of furosemide on urinary acidification may
not be apparent at high rates of urine flow. Earlier studies in
humans 37, 38] failed to detect this action of furosemide
probably because urinary acidification was evaluated when the
diuretic effect of the drug was maximal. The influence of urine
flow on the ability to lower urine pH is apparent from the
inspection of Figure 2. At very high urine flow rates (that is,
above 10 ml/min) urine pH was often (but not always) higher
than 5.5. This may be due, at least in part, to the dilutional
effect of a high urine flow on urinary H± concentration 39J. In
addition, furosemide has weak carbonic anhydrase inhibitory
properties which could result in inhibition of proximal HCO3
reabsorption and account for the increase in HCO3 excretion
observed when the concentration of the drug in the renal tubule
was probably the highest (that is, in the second hour, Fig. 3).
Thus, the optimal time for assessment of the stimulatory effect
of furosemide on H± secretion by the CCT is approximately
120 minutes following its oral administration, a time when such
action was prevented by amiloride.
That amiloride markedly attenuated the kaliuretie effect of
furosemide indicates that the increase in K+ secretion ob-
served when furosemide was given alone was due, in part, to an
increase in transepithelial voltage in the CCT. An additional
effect of furosemide on renal K+ excretion independent of its
postulated indirect effect of CCT transepithelial voltage is
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Furosemide failed to lower urine pH below 5.5 and to
increase net acid excretion in each of the six patients studied
(Fig. 8). By contrast, in the four control subjects with chronic
renal insufficiency urine pH fell below 5.5 (range 4.83 to 5.46).
Consequently, urine pH after furosemide was significantly
higher in patients with hyperkalemic DRTA than in controls
with reduced GFR (Table 3). Net acid excretion was lower in
patients than in controls but the difference did not achieve
statistical significance.
In patients with hyperkalemie DRTA, absolute K+ excretion
increased moderately but significantly (Fig. 8, Table 3). This
increase in K+ excretion, however, was blunted when com-
pared to that seen in control subjects with chronic renal
insufficiency (45 7.3 and 96 54 pFq/min, respectively, P C
0.005). fliER, urine flow, and Na excretion were not signifi-
cantly different between the two groups. In patients, neither
PRA nor PA increased significantly after furosemide adminis-
tration (from 1.2 0.6 to 1.4 ng/ml/hr, and from 9.7 2.0
to 11.7 3.4 ng/dI, respectively). ln controls with chronic renal
insufficiency, PA also did not increase in response to furose-
300 900 1500 2100 2700 3300 mide (from 37 17 to 37 17 ng/dl).
u50xv, jiEq/min
Fig. 5. The relation between K+ and Na+ excretion. Symbols as in
Figure 4.
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Table 2. Effect of furosemide and sodium sulfate on urinary acidification in patients with classic RTA
GFR V Blood Urine pEq/min
mi/mm mI/mm pH pH TAxV NH4xV HCOxV Net acid UNXV UCLXV UKXV
Baseline (N = 7) 61 1.3 7.33 6.61 7.3 7.2 11 3.8 72 105 51
±13 ±0.3 ±0.04 ±0.26 ±2.6 ±1.4 ±6.4 ±9.8 ±12 ±32 ±10
P value NS <0.01 NS <0.001 <0.02 NS NS <0.02 <0.02 <0.01 <0.01
Furosemide (N = 7) 60 5.8 7.34 6.08 19 12 13 18 550 629 110
±13 ±1.4 ±0.03 ±0.28 ±4.9 ±2.1 ±9.4 ±12 ±139 ±152 ±21
Baseline (N = 6) 78 1.9 7.40 6.85 7.5 5.6 12 1.2 95 88 43
±19 ±0.8 ±0.01 ±0.23 ±3.9 ±0.7 ±5.7 ±8.6 ±2.3 ±26 ±14
P value NS <0.001 NS <0.05 NS <0.05 <0.01 <0.02 <0.005 NS <0.05
Na2SO4 (N = 6) 79 3.4 7.39 6.07 9.9 12 8.2 12.5 362 85 100
±18 ±0.9 ±0.008 ±0.39 ±3.7 ±3.3 ±5.1 ±9.3 ±42 ±37 ±25
Pa NS NS NS NS NS NS NS NS NS <0.01 NS
a Statistical comparison between dati obtained after furosemide and sodium sulfate administration.
Table 3. Effect of furosemide in patients with hyperkalemic DRTA and in controls with chronic renal insufficiency
GFR Plasma pEq/min
ml! V K mEq/ Blood Urine Net
mm mI/mm liter pH pH UHCOXV TA NH4 acid UNaXV UxV UKXV
Patients (N = 6)
Baseline 32 1.9 4.1 7.31 6.17 2.8 21 15 34 116 116 23
±9.0 ±0.4 ±0.2 ±0.03 ±0.25 ±1.4 ±7.3 ±4.4 ±6.5 ±13 ±16 ±2.7
P value NS <0.001 NS NS NS N5 NS NS NS <0.005 <0.005 <0.025
Furosemide 33 3.9 4.6 7.33 6.06 9.5 23 15 29 366 382 45
±12 ±0.5 ±0.2 ±0.03 ±0.31 ±8.3 ±9.2 ±6.2 ±16 ±44 ±48 ±7.4
Controls (N = 4)
Baseline 44 0.8 4.6 7.32 5.41 0.08 31 9.6 41 50 58 35
±6.7 ±0.02 ±0.2 ±0.01 ±0.15 ±0.02 ±10 ±1.4 ±11 ±7.2 ±7.2 ±4.5
P value N5 0.01 NS NS 0.05 NS NS NS NS 0.01 0.01 0.01
Furosemmide 47 5.6 4.1 7.35 5.09 0.52 38 13 50 568 634 96
±8.4 ±0.9 ±0.05 ±0.03 ±0.13 ±0.3 ±8.5 ±1.7 ±7.2 ±94 ±103 ±5.4
Pa NS NS NS NS 0.025 NS NS NS NS NS 0.05 0.005
a Statistical comparison between patients and controls studied after furosemide.
apparent from the finding that K+ excretion increased linearly
as a function of urine flow (Fig. 4). This is in agreement with
previous work showing that K+ secretion by the distal tubule is
importantly influenced by tubular flow rate [40]. In contrast,
K+ secretion in the CCT, the locus of action of amiloride, is
unaffected by varying axial volume flow [21]. The difference in
K+ excretion observed at comparable urine flow rates when
furosemide was given alone and when it was given with
amiloride (Fig. 4) represents the contribution of the amiloride—
sensitive (that is, voltage—dependent) component of distal neph-
ron K+ secretion which occurs in the CCT,
It should be noted that the in vivo effect of furosemide on
CCT acidification and K+ secretion is, at least in part, an
indirect one because the drug in itself neither stimulates H+
secretion in vitro [29, 30] nor does it affect the transepithelial
voltage when added to rabbit CCT perfused in vitro [29]. In the
only study available using human CCT perfused in vitro,
however, furosemide addition to the perfusate resulted in
reduction in transepithelial voltage, a finding consistent with an
inhibitory effect on electrogenic chloride reabsorption [41]. This
effect, coupled with enhancement of Na transport owing to
increased delivery, is apt to markedly increase CCT lumen
negativity and thus H+ and K+ secretion. Furosemide, by
causing volume depletion, could also result in an acute rise in
aldosterone. This hormone is known to enhance sodium—
dependent H+ secretion in the CCD [20, 22] as well as
sodium—independent H+ secretion in the MCT [24]. In the
present study, however, a significant increase in PA after
furosemide administration was not found. That this diuretic is
capable of increasing CCT acidification independently of aldos-
terone is further supported by recent work showing that in
adrenalectomized rats, furosemide given acutely increased uri-
nary acidification to the same extent as it did in adrenal—intact
animals [42]. A stimulatory effect of furosemide on MCT
acidification can be excluded with reasonable certainty because
in this nephron segment, acidification is not voltage—dependent
[23, 241.
Other potential acute effects of furosemide on urinary acidi-
fication also need to be considered. Good [43] has recently
shown that furosemide (10-4 M) added to cortical thick ascend-
ing limbs perfused in vitro increased HCO3 absorption and that
amiloride (10-5 M) inhibited this process. It seems logical that in
vivo, such an effect of furosemide should be maximal at the
time of the peak diuretic effect of the drug (that is, 60 to 120
minutes after is oral administration). At this time, however,
HCOI excretion did not decrease but it rather increased (Fig. 3).
Accordingly, it seems unlikely that enhancement of HCO3
transport in the thick ascending limb by furosemide contributed
C F C Na2SO4 C F C Na2SO4
Fig. 6. The effect of furosemide (F) and sodium sulfate (Na2 SO4) on
urine pH (left two panels) and net acid excretion (right two panels) in
patients with classic RTA. C denotes control data. Patients 3 and 6 are
represented by open circles. The remaining five patients (1, 2, 4, 5, and
7) in whom urine pH could not be lowered below 6.0 are represented by
closed circles.
to the increase in net urinary acidification found in the present
study.
In patients with classic RTA, the infusion of sodium sulfate,
an agent believed to enhance sodium—dependent distal acidifi-
cation, resulted in a fall in urine pH in the patients in whom
furosemidc lowered it, but not in those in whom it did not (Fig.
6). The concordance of responses to furosemide and sodium
sulfate in all patients studied supports the view that the effect of
both agents on urine pH is mediated by a similar mechanism.
The infusion of sodium sulfate provides a poorly reabsorbable
anion as well as a Na load, which when reabsorbed by the CCT
results in an increase in transepithelial voltage. An increase in
CCT transepithelial voltage in response to furosemide would
occur only if Na were to be reabsorbed well in excess of Cl.
Both maneuvers therefore are associated with enhanced tubular
reabsorption of Na, but differ in that Cl reabsorption relative to
Na is depressed after furosemide administration (that is, in the
latter circumstance Cl behaves as a poorly reabsorbable anion).
A scheme for the interpretation of the distinctive responses to
furosemide and sodium sulfate found in patients with DRTA is
presented in Table 4. The CCT could be deranged in that either
the number (or function) of proton pumps is reduced or in that
the ability to generate a normal transepithelial voltage is im-
paired (or both). If the CCT were only abnormal in its ability to
maintain a large transepithelial voltage, H+ ion secretion would
still be defective even if the number and function of the proton
secretory pumps were normal. This is supported by the finding
that when amiloride was given to produce an isolated
voltage—dependent defect in the CCT, urine pH could not be
lowered (Fig. 3), and the kaliuretic effect of furosemide was
blunted (Figs. 4 and 5). If only the proton pump were impaired,
the administration of either furosemide or sodium sulfate should
increase transepithelial voltage in the CCT. In this situation,
K+ excretion would increase normally but urine pH could not
be lowered maximally owing to primary proton pump failure.
According to this scheme, the patients who exhibited an in-
crease in K+ excretion but were unable to lower urine pH
below 5.5 after furosemide and sodium sulfate administration
can be classified as having a proton pump defect involving the
CCT. This is not to say, however, that a proton pump defect in
C F C Na2SO4
Fig. 7. The effect offurosemide (F) and sodium sulfate on K+ excretion
in patients with classic RTA. Symbols as in Figure 6.
C F
Fig. 8. The effect offurosemide (F) on urine p1!, net acidexcretion and
K+ excretion in six patients with hyperkalemic DRTA.
the CCT needs to be confined to this nephron segment, because
an identical pattern would be found if the defect affected the
collecting tubule in its entirety. In the two patients with DRTA
in whom K+ excretion increased and urine pH fell below 5.3
after both furosemide and sodium sulfate administration, the
CCT must have sufficient proton pumps to secrete H+ when a
favorable transepithelial voltage is imposed by these maneu-
vers. By exclusion, their defect in distal acidification, uncov-
ered by the failure to lower urine pH despite acidemia, must be
located in the MCT and confined to this nephron segment.
One could argue that normal lowering of urine pH after
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Table 4.
Type of defect
.Site of
defect
Un ne PH K excretion
ExamplesAcidosis Furosemide Baseline Furosemide
Proton pump failure CCT >5.5 >5.5 normal normal Patients 1, 2, 4, 5, and 7 (Figs. 6 and 7)
Proton pump failure MCT >5.5 <5.5 normal normal Patients 3 and 6 (Figs. 6 and 7)
Voltage—dependent defect CCT >5.5 >5.5 decreased decreased Amiloride (Figs. 3. 4 and 5)
Voltage—dependent and CCTU >5.5 >5.5 decreased decreased Patients 1—6 (Table 4, Fig. 8)
proton pump failure
a A proton pump defect involving the MCT is present.
furosemide in patients with DRTA simply denotes the existence
of a mild proton pump defect in the CCT, a possibility that can
not be excluded from the present study. In some patients with
DRTA, the CCT is clearly capable of generating a steep pH
gradient (that is, urine pH less than 5.3) when voltage—depend-
ent acidification is acutely recruited by furosemide or sodium
sulfate. Inasmuch as the response to these agents is similar to
that observed in normal individuals, it seems reasonable to
conclude that, in certain patients with DRTA, CCT function is
normal. This view assumes that with the administration of these
agents tubular fluid pH normally falls below 5.3 at the level of
the CCT, a notion which requires validation by direct intratu-
bular pH measurements. One other interpretation for lowering
of urine pH after the administration of sodium sulfate or loop
diuretics is the existence of a gradient type of DRTA. In this
theoretical type of DRTA, abnormal proton back—leak would be
attenuated by an increase in lumen negativity secondary to the
administration of these agents, thereby allowing for maximal
lowering of urine pH [14, 34, 44]. The distinctive feature of a
gradient type of DRTA, as deduced from recent experimental
studies using Amphotericin B [441, should be a normal increase
in urine pCO2 in a highly alkaline urine, a finding never
documented in any patient with DRTA. Thus, the existence of
a gradient type of DRTA, other than that caused by Ampho-
tericin B, in my view, remains unproven.
In patients with hyperkalemic DRTA the response to furose-
mide was characterized by both inability to lower urine pH and
subnormal K excretion, a pattern identical to that reported in
some patients with hyperkalemic DRTA studied using sodium
sulfate [71. By contrast, in patients with hyperkalemic meta-
bolic acidosis associated with selective aldosterone deficiency,
furosemide [42] and sodium sulfate administration [61 have been
shown to result in maximal lowering of urine pH. The pattern
found in patients with hyperkalemic DRTA could be accounted
solely on the basis of an isolated voltage—dependent defect in
the CCT, such as was seen in normal subjects given amiloride.
One must emphasize that a similar pattern would be found if, in
addition to a CCT defect, a proton pump defect existed in the
CCT, MCT or both (Table 4). A compensatory increase in
acidification by the MCT, a segment with a large capacity for
H+ secretion [23, 25], could prevent or mitigate the develop-
ment of metabolic acidosis only if the CCT was abnormal. The
lack of overt metabolic acidosis in subjects chronically treated
with amiloride [451 provides indirect evidence for this conten-
tion. The development of frank metabolic acidosis in patients
with hyperkalemic DRTA, on the other hand, suggests the
additional presence of a proton pump defect involving the
collecting tubule in its entirety. This kind of structural involve-
ment could also be anticipated from the causes of renal disease
usually associated with hyperkalemic DRTA [7, 8].
In summary, this study shows that in normal subjects,
furosemide elicits an increase in voltage—dependent H+ and
K+ secretion in the CCT, thereby providing information as to
whether this nephron segment is able to generate a steep pH
gradient and secrete K+ normally. In patients with classic
RTA, H+ secretion may be defective owing to proton pump
failure involving the CCT (urine pH higher than 5.5 after
furosemide) or only the MCT (urine pH less than 5.5 after
furosemide). Whether a pure proton pump defect affects the
collecting tubule in its entirety or it is confined to the MCT, K+
excretion in patients with classic RTA is intact owing to
preserved ability to generate a normal voltage in the CCT. In
patients with hyperkalemic DRTA, decreased K+ excretion
and inability to lower urine pH below 5.5 after furosemide
suggest that voltage—dependent acidification in the CCT is
impaired. This type of defect likely coexist with a proton pump
defect that affects the entire collecting tubule.
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